Galecto Biotech AB has divulged new galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.
The 2022 Nobel Prize in chemistry was awarded to Carolyn Bertozzi of Stanford University, to Morten Meldal of the University of Copenhagen, and – for the second time – to Barry Sharpless of The Scripps Research Institute “for the development of click chemistry and bioorthogonal
Click chemistry, the Nobel Committee’s Olof Ramström told reporters while announcing the prize, “is almost like it sounds – it’s all about linking different molecules.”
He likened click chemistry to a seatbelt buckle, whose interlocking parts can be attached to many different materials, linking them by snapping the two parts of the buckle together.
“The problem was to find good chemical buckles,” Ramström said – chemicals that “will easily snap together, and importantly, they won’t snap with anything else.”
Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia, have developed a new genome editing technique than can activate any gene, including those that have been silenced, allowing new drug targets and causes of drug resistance to be explored.
Sibylla Biotech Srl raised €23 million (US$22.9 million) in series A funding to progress its two lead programs in targeted protein degradation, to broaden its pipeline, and to enhance its computationally intensive discovery platform. The company is expanding the druggable proteome in a highly original fashion. It applies mathematical techniques originally developed in theoretical physics to simulating the intermediate folding states of target proteins that have no obvious drug-binding pockets. These may well have transient structures that a small molecule can bind. So instead of drugging the native, biologically active molecule, it aims to develop small-molecule drugs that lock them into an intermediate state. They are then eliminated by the usual protein degradation pathways that operate within cells.
The U.S. FDA has approved Taiho Oncology Inc.’s Lytgobi (futibatinib) for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR-2) gene fusions or other rearrangements. The approval arrived on its Sept. 30 PDUFA date.
Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan.